PlainPharmaWatch

CMS Open Payments · Program Year 2024

Gamida Cell Inc.

Gamida Cell Inc. reported $372,439.78 across General Payments, Research, and Ownership to 26 physicians and teaching hospitals across 48 transactions.

See the rankings → How this is sourced
$372.4K Above-median payer
All-tracks total
48 Below-median volume
Transactions
26 Below-median reach
Recipients
#848
of 1,925 companies

Gamida Cell Inc. reported $372,439.78 across all CMS Open Payments tracks (General + Research + Ownership) to 26 physicians and teaching hospitals in Program Year 2024 - ranking #848 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $31,545.94, averaging $14.3K per recipient.

How Gamida Cell Inc.'s $372.4K all-tracks total breaks down

Gamida Cell Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

14/100

Total payments

F

13/100

Transaction volume

F

10/100

Physician reach

F

10/100

Payment type diversity

F

23/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer gamida-cell-inc Gamida Cell Inc.

$372.4K · #848/1,925 · 0.0% industry · PY2024

  • TOT $372.4K
  • RANK #848
  • SHARE 0.0%
  • TXN 48
  • RCP 26
  • CAT 2
  • GEN $31.5K
  • TOP1 19.2%
  • PY 2024

Volume peers

Nearest volume peer: Curiteva, Inc. ($373.8K)

American Regent$375.1KAltus Partners. LLC$374.7KAmerican Orthodontics Corpor…$374.7KCuriteva, Inc.$373.8KGamida Cell Inc. (this)$372.4K
All-tracks payment totals near Gamida Cell Inc. (CMS Open Payments PY2024)

Gamida Cell Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Gamida Cell Inc.

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Gamida Cell Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $30.4K across 11 transactions, 96.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads Gamida Cell Inc.'s 2-category general-payment breakdown at $30.4K, 96.5% of the reported total.

How Gamida Cell Inc. divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$30.4K2. Food and Beverage$1.1K
Payment Type Amount Transactions
Consulting Fee $30.4K 11
Food and Beverage $1.1K 15

Recipient Concentration in General Payments

The five largest recipient relationships account for $19,672.79 (62.4%) of $31,545.94 in this company's General Payments records across 22 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Gamida Cell Inc.

The five named recipients with the highest reported General Payments from this company

Leland Metheny$6.0KKoen Van Besien$5.0KFilippo Milano$3.5KGeorge Yaghmour$2.5KPatrick Stiff$2.5K
  1. 1

    Leland Metheny

    $6,050.00 across 2 reported transactions

  2. 2

    Koen Van Besien

    $5,000.00 across 1 reported transactions

  3. 3

    Filippo Milano

    $3,522.79 across 2 reported transactions

  4. 4

    George Yaghmour

    $2,550.00 across 1 reported transactions

  5. 5

    Patrick Stiff

    $2,550.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Gamida Cell Inc.'s spend rank (#848 of 1,925, top 44% by spend) and concentration rank (#978 of 1,838, bottom 47% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.

00.30.50.81.111171122.511281133.51139Total payments ($M)Concentration (HHI, 0-10,000)
Gamida Cell Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Gamida Cell Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Gamida Cell Inc..

Voom Medical Devices, Inc.

HHI 1125

Prismatik Dentalcraft, Inc.

HHI 1132

Cryo Specialty Medical, LLC

HHI 1121

MeMed US, Inc.

HHI 1121

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Gamida Cell Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Gamida Cell Inc. ranks #848 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Gamida Cell Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.